본문 바로가기
KERD
논문KCI 등재

Acid sphingomyelinase as a pathological and therapeutic target in neurological disorders: focus on Alzheimer’s disease

배재성|Choi Byung Jo|Park Min Hee|Jin Hee Kyung
생화학분자생물학회 (Korean Society Of Biochemistry And Molecular Biology)|2024.12|Experimental and Molecular Medicine|제56권 |pp. 301-310|DOI 10.1038/s12276-024-01176-4

2

조회

0

다운로드

0

인용

0

참고문헌

주제분류생화학

초록

Over the past decade, numerous studies have highlighted the importance of acid sphingomyelinase (ASM) in disease treatment in humans. This enzyme functions primarily to generate ceramide, maintain the cellular membrane, and regulate cellular function. However, in the blood and brain of patients with neurological disorders, including major depression, ischemic stroke, amyotrophic lateral sclerosis, multiple sclerosis, and Alzheimer’s disease (AD), elevated ASM levels significantly suggest disease onset or progression. In these diseases, increased ASM is profoundly involved in neuronal death, abnormal autophagy, neuroinflammation, blood–brain barrier disruption, hippocampal neurogenesis loss, and immune cell dysfunction. Moreover, genetic and pharmacological inhibition of ASM can prevent or ameliorate various diseases. The therapeutic effects of ASM inhibition have prompted the urgent need to develop ASM inhibitors, and several ASM inhibitors have been identified. In this review, we summarize the current knowledge on the critical roles and mechanisms of ASM in brain cells and blood that are associated with different neuropathological features, especially those observed in AD. Furthermore, we elucidate the potential possibility and limitations of existing ASM-targeting drugs according to experimental studies in neurological disorder mouse models.

Abstract

Over the past decade, numerous studies have highlighted the importance of acid sphingomyelinase (ASM) in disease treatment in humans. This enzyme functions primarily to generate ceramide, maintain the cellular membrane, and regulate cellular function. However, in the blood and brain of patients with neurological disorders, including major depression, ischemic stroke, amyotrophic lateral sclerosis, multiple sclerosis, and Alzheimer’s disease (AD), elevated ASM levels significantly suggest disease onset or progression. In these diseases, increased ASM is profoundly involved in neuronal death, abnormal autophagy, neuroinflammation, blood–brain barrier disruption, hippocampal neurogenesis loss, and immune cell dysfunction. Moreover, genetic and pharmacological inhibition of ASM can prevent or ameliorate various diseases. The therapeutic effects of ASM inhibition have prompted the urgent need to develop ASM inhibitors, and several ASM inhibitors have been identified. In this review, we summarize the current knowledge on the critical roles and mechanisms of ASM in brain cells and blood that are associated with different neuropathological features, especially those observed in AD. Furthermore, we elucidate the potential possibility and limitations of existing ASM-targeting drugs according to experimental studies in neurological disorder mouse models.

참고문헌 (102)

  1. Lahiri, S., "The metabolism and function of sphingolipids and glycosphingolipids", Cell. Mol. Life Sci, 64, pp.2270~2284 (2007)
  2. Hannun, Y. A., "Sphingolipids and their metabolism in physiology and disease", Nat. Rev. Mol. Cell Biol, 19, pp.175~191 (2018)
  3. Lee, M., "Functional roles of sphingolipids in immunity and their implication in disease", Exp. Mol. Med, 55, pp.1110~1130 (2023)
  4. Piccinini, M., "Deregulated sphingolipid metabolism and membrane orga nization in neurodegenerative disorders", Mol. Neurobiol, 41, pp.314~340 (2010)
  5. Olsen, A. S. B., "Sphingolipids: membrane microdomains in brain development, function and neurological diseases", Open Biol, 7, pp.170069~ (2017)
  6. Astudillo, L., "Human genetic disorders of sphingolipid biosynthesis", J. Inherit. Metab. Dis, 38, pp.65~76 (2015)
  7. Schissel, S. L., "Zn2+-stimulated sphingomyelinase is secreted by many cell types and is a product of the acid sphingomyelinase gene", J. Biol. Chem, 271, pp.18431~18436 (1996)
  8. Jana, A., "Ceramide and neurodegeneration: suscept ibility of neurons and oligodendrocytes to cell damage and death", J. Neurol. Sci, 278, pp.5~15 (2009)
  9. Petrache, I., "Ceramide upregulation causes pulmonary cell apoptosis and emphysema-like disease in mice", Nat. Med, 11, pp.491~498 (2005)
  10. Toman, R. E., "Role of ceramide in neuronal cell death and differentiation", J. Neurotrauma, 17, pp.891~898 (2000)
  11. Gaggini, M., "Ceramides as mediators of oxidative stress and inflammation in cardiometabolic disease", Int. J. Mol. Sci, 23, pp.2719~ (2022)
  12. Trayssac, M., "Role of sphingolipids in senescence : implication in aging and age-related diseases", J. Clin. Investig, 128, pp.2702~2712 (2018)
  13. Schissel, S. L., "The cellular trafficking and zinc dependence of secretory and lysosomal sphingo myelinase, two products of the acid sphingomyelinase gene", J. Biol. Chem, 273, pp.18250~18259 (1998)
  14. Jenkins, R. W., "Roles and regulation of secretory and lysosomal acid sphingomyelinase", Cell Signal, 21, pp.836~846 (2009)
  15. Kornhuber, J., "Secretory sphingomyelinase in health and disease", Biol. Chem, 396, pp.707~736 (2015)
  16. Breiden, B., "Acid sphingomyelinase, a lysosomal and secretory phospholipase C, is key for cellular phospholipid catabolism", Int. J. Mol. Sci, 22, pp.9001~ (2021)
  17. Ferlinz, K., "Molecular basis of acid sphingomyelinase deficiency in a patient with Niemann-Pick disease type A", Biochem. Biophys. Res. Commun, 179, pp.1187~1191 (1991)
  18. Kornhuber, J., "High activity of acid sphingomyelinase in major depression", J. Neural Transm, 112, pp.1583~1590 (2005)
  19. Choi, B. J., "Acid sphingomyelinase inhibition improves motor behavioral deficits and neuronal loss in an amyotrophic lateral sclerosis mouse model", BMB Rep, 55, pp.62~626 (2022)
  20. Ong, W. Y., "Role of sphin gomyelinases in neurological disorders", Expert. Opin. Ther. Targets, 19, pp.1725~1742 (2015)
  21. Park, M. H., "Potential therapeutic target for aging and age related neurodegenerative diseases : the role of acid sphingomyelinase", Exp. Mol. Med, 52, pp.380~389 (2020)
  22. Kirschnek, S., "CD95-mediated apoptosis in vivo involves acid sphingo myelinase", J. Biol. Chem, 275, pp.27316~23723 (2000)
  23. Smith, E. L., "The unexpected role of acid sphingomyelinase in cell death and the pathophysiology of common diseases", FASEB J, 22, pp.3419~3431 (2008)
  24. Park, M. H., "Vascular and neurogenic rejuvenation in aging mice by modulation of ASM", Neuron, 100, pp.167~182 (2018)
  25. Lee, J. K., "Acid sphingomyelinase modulates the autophagic process by controlling lysosomal biogenesis in Alzheimer’s disease", J. Exp. Med, 211, pp.1551~1570 (2014)
  26. Choi, B. J., "Immunotherapy targeting plasma ASM is protective in a mouse model of Alzheimer’s disease", Nat. Commun, 14, pp.1631~ (2023)
  27. Burgunder, J. M., "Mechanisms underlying phenotypic variation in neurogenetic disorders", Nat. Rev. Neurol, 19, pp.363~370 (2023)
  28. Wouk, J., "Viral infections and their relationship to neurological disorders", Arch. Virol, 166, pp.733~753 (2021)
  29. Aleya, L., "Environmental pollutants and the risk of neurological disorders", Environ. Sci. Pollut. Res. Int, 27, pp.44657~44658 (2020)
  30. Liewluck, T., "Immune-mediated neurological disorders", Curr. Neurol. Neurosci. Rep, 15, pp.61~ (2015)
  31. Dumurgier, J., "Epidemiology of neurological diseases in older adults", Rev. Neurol, 176, pp.642~648 (2020)
  32. Moujalled, D., "Molecular mechanisms of cell death in neurological diseases", Cell Death Differ, 28, pp.2029~2044 (2021)
  33. Lepeta, K., "Synaptopathies : synaptic dysfunction in neurological disorders —a review from students to students", J. Neurochem, 138, pp.785~805 (2016)
  34. Mishra, A., "Neuroinflammation in neurological disorders : pharmacother apeutic targets from bench to bedside", Metab. Brain Dis, 36, pp.1591~1626 (2021)
  35. Rosenberg, G. A., "Neurological diseases in relation to the blood–brain barrier", J. Cereb. Blood Flow. Metab, 32, pp.1139~1151 (2012)
  36. Ross, C. A., "Protein aggregation and neurodegenerative disease", Nat. Med, 10(Suppl), pp.S10~S17 (2004)
  37. Yu, Z. F., "Pivotal role for acidic sphingomyelinase in cerebral ischemia induced ceramide and cytokine production, and neuronal apoptosis", J. Mol. Neurosci, 15, pp.85~97 (2000)
  38. Cutler, R. G., "Evidence that accumulation of ceramides and cholesterol esters mediates oxi dative stress-induced death of motor neurons in amyotrophic lateral sclerosis", Ann. Neurol, 52, pp.448~457 (2002)
  39. Han, X., "Lipid alterations in the earliest clinically recognizable stage of Alzhei mer’s disease : implication of the role of lipids in the pathogenesis of Alzheimer’s disease", Curr. Alzheimer Res, 2, pp.65~77 (2005)
  40. Lee, J. K., "ASM in Alzheimer’s disease", Oncotarget, 6, pp.39389~39390 (2015)
  41. He, X., "Deregulation of sphingolipid metabolism in Alzheimer’s disease", Neurobiol. Aging, 31, pp.398~408 (2010)
  42. Dias, I. H., "Oxidized LDL lipids increase beta-amyloid production by SH SY5Y cells through glutathione depletion and lipid raft formation", Free Radic. Biol. Med, 75, pp.48~59 (2014)
  43. Park, M. H., "Discovery of a dual-action small molecule that improves neuropathological features of Alzheimer’s disease mice", Proc. Natl Acad. Sci. USA, 119, pp.e2115082119~ (2022)
  44. Gulbins, E., "Acid sphingomyelinase-ceramide system mediates effects of antidepressant drugs", Nat. Med, 19, pp.934~938 (2013)
  45. Gulbins, E., "A central role for the acid sphingomyelinase", ceramide system in neurogenesis and major depression, 2015, pp.134, 183~192
  46. David, D. J., "Neurogenesis-dependent and-independent effects of fluox etine in an animal model of anxiety", depression, 2009, pp.62, 479~493
  47. Santarelli, L., "Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants", Science, 301, pp.805~809 (2003)
  48. Warner-Schmidt, J. L., "Hippocampal neurogenesis : opposing effects of stress and antidepressant treatment", Hippocampus, 16, pp.239~249 (2006)
  49. Glick, D., "Autophagy : cellular and molecular mechanisms", J. Pathol, 221, pp.3~12 (2010)
  50. Nixon, R. A., "The role of autophagy in neurodegenerative disease", Nat. Med, 19, pp.983~997 (2013)
  51. Bento, C. F., "Mammalian autophagy: how does it work?", Annu. Rev. Biochem, 85, pp.685~713 (2016)
  52. Pattingre, S., "Ceramide-induced autophagy: to junk or to protect cells?", Autophagy, 5, pp.558~560 (2009)
  53. Jiang, W., "Autophagy paradox and ceramide", Biochim Biophys. Acta, 1841, pp.783~792 (2014)
  54. Menon, M. B., "Beclin 1 phosphorylation-at the center of autop hagy regulation", Front Cell Dev. Biol, 6, pp.137~ (2018)
  55. Tran, S., "BECLIN1 : protein structure, function and regulation", Cells, 10, pp.1522~ (2021)
  56. O’Brien, W. T., "The NLRP3 inflammasome in traumatic brain injury : potential as a biomarker and therapeutic target", J. Neuroinflamm, 17, pp.104~ (2020)
  57. Hanslik, K. L., "The role of microglia and the Nlrp3 inflammasome in Alzheimer’s disease", Front. Neurol, 11, pp.570711~ (2020)
  58. Song, L., "NLRP3 inflammasome in neurological diseases, from functions to therapies", Front. Cell Neurosci, 11, pp.63~ (2017)
  59. Li, C., "Crosstalk between acid sphingomyelinase and inflammasome signaling and their emerging roles in tissue injury and fibrosis", Front. Cell Dev. Biol, 7, pp.378~ (2020)
  60. Novgorodov, S. A., "Acid sphingomyelinase deficiency protects mitochondria and improves function recovery after brain injury", J. Lipid Res, 60, pp.609~623 (2019)
  61. van Doorn, R., "Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes", Acta Neuro pathol, 124, pp.397~410 (2012)
  62. Tian, H. P., "Sphingomyelinase-induced ceramide production stimulate calcium-independent JNK and PP2A activation following cerebral ischemia", Brain Inj, 23, pp.1073~1080 (2009)
  63. Parton, R. G., "Caveolae as plasma membrane sensors, protectors and organizers", Nat. Rev. Mol. Cell Biol, 14, pp.98~112 (2013)
  64. Villaseñor, R., "Intracellular transport and regulation of transcytosis across the blood-brain barrier", Cell. Mol. Life Sci, 76, pp.1081~1092 (2019)
  65. Zhao, Y. L., "Role of caveolin-1 in the biology of the blood brain barrier", Rev. Neurosci, 25, pp.247~254 (2014)
  66. Stahlhut, M., "Identification of filamin as a novel ligand for caveolin-1 : evidence for the organization of caveolin-1-associated membrane domains by the actin cytoskeleton", Mol. Biol. Cell, 11, pp.325~337 (2000)
  67. Sverdlov, M., "Filamin A regulates caveolae internalization and trafficking in endothelial cells", Mol. Biol. Cell, 20, pp.4531~4540 (2009)
  68. Pinheiro, M. A. L., "Acid sphingomyelinase-derived ceramide regulates ICAM 1 function during T cell transmigration across brain endothelial cells", J. Immunol, 196, pp.72~79 (2016)
  69. Becker, K. A., "Blockade of experimental multiple sclerosis by inhibition of the acid sphingomyelinase", ceramide system, 2017, pp.25, 88~97
  70. Leurs, C. E., "Acid sphingomyelinase : no potential as a biomarker for mul tiple sclerosis", Mult. Scler. Relat. Disord, 28, pp.44~49 (2019)
  71. Mejzini, R., "ALS genetics, mechanisms, and therapeutics: where are we now?", Front Neurosci, 13, pp.1310~ (2019)
  72. Kim, G., "ALS genetics : gains, losses, and implications for future therapies", Neuron, 108, pp.822~842 (2020)
  73. Vance, C., "Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6", Science, 323, pp.1208~1211 (2009)
  74. Lang, U. E., "Molecular mechanisms of depression: perspectives on new treatment strategies", Cell Physiol. Biochem, 31, pp.761~777 (2013)
  75. Jin, J., "Acid sphingomyelinase plays a key role in palmitic acid-amplified inflammatory signaling triggered by lipopolysaccharide at low concentrations in macrophages", Am. J. Physiol. Endocrinol. Metab, 305, pp.E853~E867 (2013)
  76. Rozenova, K. A., "Studies on the role of acid sphingomyelinase and ceramide in the regulation of tumor necrosis factor alpha(TNFalpha)-converting enzyme activity and TNFal pha secretion in macrophages", J. Biol. Chem, 285, pp.21103~21113 (2010)
  77. Rochfort, K. D., "The blood–brain barrier endothelium : a target for pro-inflammatory cytokines", Biochem. Soc. Trans, 43, pp.702~706 (2015)
  78. Huang, X., "Peripheral inflammation and blood–brain barrier disruption : effects and mechanisms", CNS Neurosci. Ther, 27, pp.36~47 (2021)
  79. Yang, J., "New insight into neurological degeneration : Inflammatory cyto kines and blood–brain barrier", Front. Mol. Neurosci, 15, pp.1013933~ (2022)
  80. Beurel, E., "Th17 cells in depression", Brain Behav. Immun, 69, pp.28~34 (2018)
  81. Moser, T., "The role of TH17 cells in multiple sclerosis : therapeutic implications", Autoimmun. Rev, 19, pp.102647~ (2020)
  82. Jin, M., "Peripheral proin f lammatory Th1", Th17 immune cell shift is linked to disease severity in amyo trophic lateral sclerosis, 2020, pp.10, 5941~
  83. Oberstein, T. J., "Imbalance of circulating Th17 and regulatory T cells in Alzheimer’s disease : a case control study", Front. Immunol, 9, pp.1213~ (2018)
  84. Tahmasebinia, F., "The role of Th17 cells in autoin f lammatory neurological disorders", Prog. Neuropsychopharmacol. Biol. Psychiatry, 79, pp.408~416 (2017)
  85. Miossec, P., "Targeting IL-17 and TH17 cells in chronic inflammation", Nat. Rev. Drug Discov, 11, pp.763~776 (2012)
  86. Maddur, M. S., "Th17 cells : biology, patho genesis of autoimmune and inflammatory diseases, and therapeutic strategies", Am. J. Pathol, 181, pp.8~18 (2012)
  87. Albouz, S., "Modifications of sphingomyelin and phosphatidylcholine metabolism by tricyclic anti depressants and phenothiazines", Life Sci, 38, pp.357~363 (1986)
  88. Kornhuber, J., "Functional inhibitors of acid sphingomyelinase(FIASMAs) : a novel pharmacological group of drugs with broad clinical applications", Cell Physiol. Biochem, 26, pp.9~20 (2010)
  89. Beckmann, N., "Inhibition of acid sphingomyelinase by tricyclic antidepressants and analogons", Front Physiol, 5, pp.331~ (2014)
  90. Jaffrézou, J. P., "Inhibition of lysosomal acid sphingomyelinase by agents which reverse multidrug resistance", Biochim. Biophys. Acta, 1266, pp.1~8 (1995)
  91. Kornhuber, J., "Identification of new functional inhibitors of acid sphingo myelinase using a structure-property-activity relation model", J. Med. Chem, 51, pp.219~237 (2008)
  92. Kornhuber, J., "The ceramide system as a novel antidepressant target", Trends Pharmacol. Sci, 35, pp.293~304 (2014)
  93. Yusuf, A. M., "Acid sphingomyelinase deactivation post-ischemia promotes brain angiogenesis and remodeling by small extracellular vesicles", Basic Res. Cardiol, 117, pp.43~ (2022)
  94. Lee, S. H., "Acid sphingomyelinase inhibitor, imipramine, reduces hippocampal neuronal death after traumatic brain injury", Int. J. Mol. Sci, 23, pp.14749~ (2022)
  95. Arenz, C., "Small molecule inhibitors of acid sphingomyelinase", Cell Physiol. Biochem, 26, pp.1~8 (2010)
  96. Naser, E., "Characterization of the small molecule ARC39, a direct and specific inhibitor of acid sphingomyelinase in vitro", J. Lipid Res, 61, pp.896~891 (2020)
  97. Darroch, P. I., "A lipid analogue that inhibits sphingomyelin hydrolysis and synthesis, increases ceramide, and leads to cell death", J. Lipid Res, 46, pp.2315~2324 (2005)
  98. Yokomatsu, T., "Synthesis of non-competitive inhibitors of sphingomyelinases with significant activity", Bioorg. Med. Chem. Lett, 13, pp.229~236 (2003)
  99. Park, M. H., "Multi-faceted small molecule for Alzheimer’s disease", Neural Regen. Res, 18, pp.2198~2199 (2023)
  100. Sevigny, J., "The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease", Nature, 537, pp.50~56 (2016)
  101. Schilling, S., "Passive Aβ immunotherapy : current achievements and future perspectives", Molecules, 23, pp.1068~ (2018)
  102. Song, C., "Immunotherapy for Alzheimer’s disease : targeting β-amyloid and beyond", Transl. Neurodegener, 11, pp.18~ (2022)

관련 논문AI추천

Acid sphingomyelinase inhibition improves motor behavioral deficits and neuronal loss in an amyotrophic lateral sclerosis mouse model김승현, Byung Jo Choi, Eric Jinsheng Huang, Hee Kyung Jin, Jae-sung Bae, Kang Ho Park, Min Hee Park생화학분자생물학회 · BMB Reports2022 · 제55권 제12호Sphingolipids in neuroinflammation: a potential target for diagnosis and therapy배재성, 이주연, 진희경생화학분자생물학회 · BMB Reports2020 · 제53권 제1호Acid sphingomyelinase-mediated blood-brain barrier disruption in aging박민희, 배재성, 진희경생화학분자생물학회 · BMB Reports2019 · 제52권 제2호Ceramide/Sphingomyelin Rheostat Regulated by Sphingomyelin Synthases and Chronic Diseases in Murine ModelsMakoto Taniguchi, Toshiro Okazaki한국지질동맥경화학회 · 지질·동맥경화학회지2020 · 제9권 제3호Functional roles of sphingolipids in immunity and their implication in disease배외식, Lee Min Gyu, Lee Suh Yeon생화학분자생물학회 · Experimental and Molecular Medicine2023 · 제55권 A Therapeutic Strategy for Alzheimer's Disease Focused on Immune-inflammatory Modulation김승현, 김희진, 노민영, 문연실, 오기욱, 진희경, Jae-Sung Bae, Jin-Seok Park, Sanggon Lee, Young-Eun Kim대한치매학회 · Dementia and Neurocognitive Disorders(대한치매학회지)2019 · 제18권 제2호

이 간행물의 다른 논문 (218건)

Big data and deep learning for RNA biologyJeon Hyeonseong, Baek Daehyun, Hwang Hyeonseo, Yeo Nagyeongpp. 1-29RGS19 activates the MYH9/β-catenin/c-Myc positive feedback loop in hepatocellular carcinomaXu Yanan, Ke Shanjia, Lu Shounan, Bai Miaoyu, Yu Hongjun, Yin Bing, Wang Chaoqun, Feng Zhigang, Li Zihao, Huang Jingjing, Li Xinglong, Qian Baolin, Hua Yongliang, Fu Yao, Sun Bei, Wu Yaohua, Ma Yongpp. 1-14Molecular mechanisms of circular RNA translationKim Yoon Ki, Hwang Hyun Jungpp. 1-9The m6A writer RBM15 drives the growth of triple-negative breast cancer cells through the stimulation of serine and glycine metabolismKim Ho, Yun Hye Jin, 이종호, Lee Su Bin, Kim Seok-Ho, Park Yun-Yong, Park Su Hwan, Ju Jin-Sung, Woo Hyunmin, Győrffy Balázs, Kim Eun-jeong, Han Hee Dong, Eyun Seong-ilpp. 1-15Neuron type-specific optogenetic stimulation for differential stroke recovery in chronic capsular infarctKim Ra Gyung, Cho Jongwook, Park Ji-Young, Kim Young Ro, Lee Min-Cheol, Kim Hyoung-Ihlpp. 1-11
원문 보기